Syngene International

    SYNGENE
    Pharma
    ₹434.80
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹17,475 Cr

    P/E
    94.11
    Day range
    ₹430.80 – ₹445.95
    52-week range
    ₹344.45 – ₹678.95
    Volume
    5.48 L
    Open
    ₹434.05
    Prev close
    ₹434.35

    Latest results · Q2 FY27(consolidated)Revenue ₹833 Cr-8.6%Profit ₹32 Cr-52.0%Margin 3.9%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 45 / 100

    Factor percentiles

    Value46
    Quality37
    Momentum47
    Low volatility49

    Derived metrics

    Earn. yield
    1.1%
    Graham no.
    ₹133.37
    vs Graham
    -69.3%
    ROE ÷ P/B
    1.8%
    12-1 mom.
    -38.7%
    Return / vol
    -0.90
    Magic Formula
    #583
    Piotroski
    2/6
    FCF yield
    3.1%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Syngene InternationalSYNGENE₹17,475 Cr94.113.626.6%10.0%18.0%0.10-8.6%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 21h ago

    Headlines about Syngene International from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    66.0
    Price / Book
    3.62
    ROE (FY26)
    6.6%
    ROCE (latest year)
    10%
    Dividend yield
    0.29%

    Moving averages (NSE)

    20-day
    ₹410.23
    Price above
    50-day
    ₹389.92
    Price above
    200-day
    ₹419.41
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +5.4%
    Profit 3Y CAGR
    -11.9%
    Revenue YoY (Sep 2026)
    -8.6%
    Profit YoY (Sep 2026)
    -52.2%
    Operating margin
    18.0%
    Net margin
    3.8%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -500 Cr0 Cr500 Cr1K Cr1.5K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 11 Jun 2019: earlier bars are per pre-bonus share.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹0.5₹1₹1.5

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales8549177908919441,0188749119171,036736833
    YoY Sales growth—-8-2-2————-3—-16-9
    Expenses622600620646660674668711708733645685
    Operating Profit23231717024528434420620020930391147
    OPM %27%35%22%27%30%34%24%22%23%29%12%18%
    Other Income2616501618191815-55161221
    Interest111312131216121312121010
    Depreciation108111107111109106111116114112112112
    Profit before tax1382091011371812401018528196-1947
    Tax %19%10%25%23%27%24%14%21%47%25%-53%31%
    Net Profit11218976106131183876715148-932
    EPS in Rs₹2.77₹4.69₹1.88₹2.64₹3.26₹4.55₹2.15₹1.67₹0.37₹3.67₹-0.22₹0.80

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days50

    -29 days since Mar 2021

    Inventory Days56

    +15 days since Mar 2021

    Days Payable138

    -29 days since Mar 2021

    Cash Conversion Cycle-32

    +15 days since Mar 2021

    Working Capital Days-68

    -2 days since Mar 2021

    Strengths, risks & growth

    Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 3.61 times its book value
    • The company has delivered a poor sales growth of 11.4% over past five years.
    • Company has a low return on equity of 10.2% over last 3 years.
    • Dividend payout has been low at 12.0% of profits over last 3 years

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +11%
    3 Years
    +5%
    TTM
    -6%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    0%
    3 Years
    -8%
    TTM
    -43%

    Stock Price CAGR

    10 Years
    +5%
    5 Years
    -6%
    3 Years
    -16%
    1 Year
    -33%

    Return on Equity

    10 Years
    —
    5 Years
    +11%
    3 Years
    +10%
    Last Year
    +8%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter52.68%52.68%52.59%52.59%0.00 pp
    FII14.96%13.91%11.82%10.13%-1.69 pp
    DII25.83%26.44%28.01%29.31%+1.30 pp
    Public6.22%6.69%7.15%7.55%+0.40 pp
    Others0.29%0.29%0.43%0.41%-0.02 pp

    Filed with NSE for Sept 2026: promoters 52.59%, public 47.00%

    Analysts & fund holdings

    75%
    75% recommend buy
    8 analysts cover the stock
    Valuation vs Life Sciences Tools & Services
    P/E94.1 vs 45.1
    Sector P/B6.03
    Beta1.18

    Who holds the shares, quarter by quarter

    Mutual funds 27.21% (+1.32 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters52.8%
    • Foreign institutions10.2%
    • Mutual funds27.2%
    • Insurance2.1%
    • Other domestic institutions0.1%
    • Retail5.0%
    • Others2.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Nippon India Small Cap Fund3.29%0.75%+0.14 pp
    ICICI Pru Multi Cap Fund1.83%1.78%+0.43 pp
    Nippon India Multi Cap Fund1.56%0.51%+0.05 pp
    ICICI Pru Healthcare Fund1.53%3.76%+0.50 pp
    Nippon India Focused Fund1.40%3.03%+0.32 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    34.6%
    Downside volatility
    33.6%
    Worst 5% of days
    3.3%
    Average of that tail
    5.1%
    Max drawdown (1Y)
    48.4%
    Below its peak
    35.2%

    Against the market

    Beta vs Nifty 50
    0.71
    Correlation
    0.28
    Relative strength (3M)
    +4.0%
    ATR (14)
    3.4%

    Return

    Return 1M
    +12.6%
    Return 3M
    +7.9%
    Return 6M
    -6.8%
    Return 1Y
    -31.0%
    vs 200-day average
    +3.7%

    Momentum

    RSI (14)
    62.2
    MACD histogram
    2.28
    Stochastic %K
    69.5
    ADX (14)
    39.1
    +DI / −DI
    30.5 / 11.5
    Money flow index
    64.7

    Participation

    Delivery (20d avg)
    48.9%
    vs its 60-day baseline
    -2.7 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.7%
    52-week position
    27 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    ₹547 Cr
    FCF yield
    3.1%
    Cash conversion
    2.89
    Accruals ratio
    -0.085
    Net debt
    ₹388 Cr
    Net debt / equity
    0.08
    EV / sales
    5.07
    Capex intensity
    9.8%
    Revenue CAGR
    -12.5%
    Profit CAGR
    -68.6%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹1.25

      Dividend - Rs 1.25 Per Share

      25 Jun 2026
      ex-date
    • dividend
      ₹1.25

      Dividend - Rs 1.25 Per Share

      27 Jun 2025
      ex-date
    • dividend
      ₹1.25

      Dividend - Rs 1.25 Per Share

      28 Jun 2024
      ex-date
    • dividend
      ₹0.50

      Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.75 Per Share

      30 Jun 2023
      ex-date
    • dividend
      ₹0.50

      Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.50 Per Share

      30 Jun 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      13 Jul 2021
      ex-date
    • dividend
      ₹0.50

      Dividend - Rs 0.50 Per Share

      16 Jul 2019
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      11 Jun 2019
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend Re - Re 1 Per Share

      17 Jul 2018
      ex-date
    • dividend
      ₹1.00

      Dividend - Rs 1/- Per Share

      20 Jul 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1/- Per Share (Purpose Revised)

      17 Mar 2016
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Conference Call for Analysts and Investors

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018.

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ending September 30, 2026.

    Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Un-Audited Standalone ....

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Closure of Trading Window

    Company Update
    Intimation Of Cancellation Of Meeting With Analyst/Institutional Investors

    Intimation of cancellation of meeting with Analyst/Institutional Investors

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Resignation of Mr. Pramuch Goel as Head Corporate Affairs & Communications and a member of Executive Committee (Senior Management Personnel) of the Company w.e.f. the close of business ....

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Meeting with Analyst/Institutional Investor

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Meeting with Analyst/Institutional Investor

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Meeting with Analyst/Institutional Investor

    Company Update
    Communication Regarding Remittance Of Final Dividend For The FY 2025-26

    Communication regarding remittance of final dividend for the FY 2025-26

    Company Update
    Grant Of Performance Share Units Under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 ('Plan')

    Grant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 ("Plan")

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Investor/Analyst Meeting with Goldman Sachs Asia Leaders Conference 2026

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Intimation of investment in Ampin C&I Power Twelve Private Limited

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Investor call schedule with Entrust Family Office

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Meeting with Analyst/Institutional Investor on August 13, 2026 and August 14, 2026.

    Filed with BSE (scrip 539268); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Syngene International: common questions

    Answered from the figures on this page.

    Syngene International last traded at ₹434.80 (NSE, as of 18 Nov 2026). The last session moved it up 0.10%.

    Syngene International is valued at about ₹17,475 crore (NSE, as of 18 Nov 2026).

    Syngene International trades at a price-to-earnings ratio of 94.11 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Syngene International has traded between ₹344.45 and ₹678.95 over the past 52 weeks, to 18 Nov 2026. It is currently 27% of the way up that range.

    Syngene International (SYNGENE) is classified under Pharma on this site's screener.